Trial Profile

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

09 Jan 2023 Status changed from recruiting to active, no longer recruiting.
13 Dec 2022 Study is expected to complete recruitment in 2022 and read primary end point in 2023, as per trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.
13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com